Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NYSE:HHH NASDAQ:TSHA NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$39.05-1.2%$32.72$23.42▼$62.58$2.29B0.73657,124 shs789,243 shsHHHHoward Hughes$70.57-0.8%$69.06$59.83▼$87.77$3.58B1.21377,966 shs450,208 shsTSHATaysha Gene Therapies$2.64+3.5%$2.54$1.05▼$3.31$547.39M0.972.94 million shs3.29 million shsVCELVericel$39.93-3.2%$41.87$37.39▼$63.00$2.08B1.32421,282 shs309,779 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+1.18%+9.64%+14.55%+48.05%-9.11%HHHHoward Hughes+1.48%+2.49%+0.58%+8.98%+7.00%TSHATaysha Gene Therapies+0.39%+6.25%-2.30%+104.82%+12.83%VCELVericel-0.65%-1.33%-9.78%-0.05%-9.28%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals4.4706 of 5 stars3.43.00.04.32.70.81.9HHHHoward Hughes2.5799 of 5 stars2.33.00.00.02.63.31.3TSHATaysha Gene Therapies4.0521 of 5 stars4.55.00.00.02.63.30.0VCELVericel3.7051 of 5 stars3.55.00.00.03.40.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.71Moderate Buy$58.6050.06% UpsideHHHHoward Hughes 2.67Moderate Buy$80.3313.83% UpsideTSHATaysha Gene Therapies 3.00Buy$8.17209.34% UpsideVCELVericel 3.00Buy$61.1453.13% UpsideCurrent Analyst Ratings BreakdownLatest TSHA, HHH, VCEL, and AGIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/11/2025TSHATaysha Gene TherapiesBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.007/1/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/23/2025HHHHoward HughesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$82.00 ➝ $76.006/16/2025VCELVericelStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$67.006/10/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/3/2025TSHATaysha Gene TherapiesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $11.006/2/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $8.005/29/2025TSHATaysha Gene TherapiesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/29/2025TSHATaysha Gene TherapiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$5.00 ➝ $6.005/29/2025TSHATaysha Gene TherapiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $9.005/23/2025HHHHoward HughesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$105.00 ➝ $85.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$36.50M61.97N/AN/A$27.02 per share1.45HHHHoward Hughes$1.75B2.03$9.61 per share7.34$56.65 per share1.25TSHATaysha Gene Therapies$8.33M68.03N/AN/A$0.35 per share7.54VCELVericel$237.22M8.47$0.30 per share131.94$5.92 per share6.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.243.47N/AN/A1,798.26%-2.75%-2.52%7/30/2025 (Estimated)HHHHoward Hughes$200.55M$5.2113.5576.71N/A14.27%10.21%3.08%N/ATSHATaysha Gene Therapies-$89.30M-$0.34N/AN/AN/A-1,201.08%-104.93%-50.09%8/11/2025 (Estimated)VCELVericel$10.36M$0.031,331.4490.75N/A1.25%1.09%0.73%7/30/2025 (Estimated)Latest TSHA, HHH, VCEL, and AGIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025AGIOAgios Pharmaceuticals-$1.74N/AN/AN/AN/AN/A8/7/2025Q2 2025VCELVericel-$0.04N/AN/AN/A$64.61 millionN/A5/15/2025Q1 2025TSHATaysha Gene Therapies-$0.08-$0.08N/A-$0.08$1.48 million$2.30 million5/8/2025Q1 2025VCELVericel-$0.09-$0.23-$0.14-$0.23$53.86 million$52.60 million5/7/2025Q1 2025HHHHoward Hughes$0.13$0.21+$0.08$0.21$187.43 million$199.33 million5/1/2025Q1 2025AGIOAgios Pharmaceuticals-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AHHHHoward HughesN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A18.5017.93HHHHoward Hughes1.841.411.41TSHATaysha Gene Therapies0.775.355.35VCELVericelN/A5.014.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AHHHHoward Hughes93.83%TSHATaysha Gene Therapies77.70%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.30%HHHHoward Hughes33.00%TSHATaysha Gene Therapies3.78%VCELVericel5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39057.92 million55.43 millionOptionableHHHHoward Hughes60850.39 million33.76 millionOptionableTSHATaysha Gene Therapies180214.66 million206.55 millionOptionableVCELVericel30050.34 million47.73 millionOptionableTSHA, HHH, VCEL, and AGIO HeadlinesRecent News About These CompaniesVericel Corporation (NASDAQ:VCEL) Receives $61.14 Average Price Target from AnalystsJuly 5, 2025 | americanbankingnews.comAllspring Global Investments Holdings LLC Sells 11,632 Shares of Vericel Corporation (NASDAQ:VCEL)July 4, 2025 | marketbeat.comVericel Corporation (NASDAQ:VCEL) Receives Consensus Rating of "Buy" from BrokeragesJuly 2, 2025 | marketbeat.comLisanti Capital Growth LLC Acquires 13,585 Shares of Vericel Corporation (NASDAQ:VCEL)June 29, 2025 | marketbeat.comIf EPS Growth Is Important To You, Vericel (NASDAQ:VCEL) Presents An OpportunityJune 20, 2025 | finance.yahoo.comConestoga Capital Advisors LLC Sells 7,830 Shares of Vericel Co. (NASDAQ:VCEL)June 17, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Shares Down 3.8% - What's Next?June 16, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Receives "Overweight" Rating from StephensJune 16, 2025 | marketbeat.comVericel Corporation: Moving From Sell To NeutralJune 12, 2025 | seekingalpha.comVericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025June 11, 2025 | morningstar.comMVericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025June 10, 2025 | globenewswire.com5VCEL : What Analysts Are Saying About Vericel StockMay 23, 2025 | benzinga.comVericel at BofA Securities Conference: Growth and Innovation in HealthcareMay 16, 2025 | investing.comWhich Is a Better Investment, BioCryst Pharmaceuticals, Inc. or Vericel Corporation Stock?May 10, 2025 | aaii.comAVericel Corporation: Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability GuidanceMay 9, 2025 | finanznachrichten.deVericel Corp (VCEL) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...May 9, 2025 | finance.yahoo.comVericel Corporation 2025 Q1 - Results - Earnings Call PresentationMay 8, 2025 | seekingalpha.comVericel Corporation (VCEL) Q1 2025 Earnings Conference Call TranscriptMay 8, 2025 | seekingalpha.comVericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue EstimatesMay 8, 2025 | zacks.comVericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability GuidanceMay 8, 2025 | globenewswire.comVericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025May 7, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTSHA, HHH, VCEL, and AGIO Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$39.05 -0.48 (-1.21%) Closing price 04:00 PM EasternExtended Trading$38.64 -0.41 (-1.06%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Howard Hughes NYSE:HHH$70.57 -0.55 (-0.77%) Closing price 03:59 PM EasternExtended Trading$70.75 +0.18 (+0.26%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Howard Hughes Holdings Inc., together with its subsidiaries, operates as a real estate development company in the United States. It operates in four segments: Operating Assets; Master Planned Communities (MPCs); Seaport; and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multi-family properties along with other retail investments. Its MPCs segment develops, sells, and leases residential and commercial land designated for long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. The Seaport segment is involved in the landlord operations, managed businesses, and events and sponsorships services of its restaurant, retail, and entertain properties in Pier 17, New York City; Historic Area/Uplands; and Tin Building, as well as in 250 Water Street and in the Jean-Georges restaurants. The Strategic Development segment develops and redevelops residential condominiums and commercial properties. It serves homebuilders. Howard Hughes Holdings Inc. was founded in 2010 and is headquartered in The Woodlands, Texas.Taysha Gene Therapies NASDAQ:TSHA$2.64 +0.09 (+3.53%) Closing price 04:00 PM EasternExtended Trading$2.64 +0.00 (+0.19%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.Vericel NASDAQ:VCEL$39.93 -1.30 (-3.15%) Closing price 04:00 PM EasternExtended Trading$39.92 -0.01 (-0.01%) As of 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
